Most peptides for GLP-1 users are research-stage, and six of them can be compounded in the US only under an interim HHS policy issued on 28 October 2026.
- Available now: tesamorelin (approved for HIV-related belly fat only) and cosmetic GHK-Cu. Compounded sermorelin sells on narrower legal footing.
- A July 2026 FDA committee backed six of seven in close votes. No rule changed.
- The FDA’s next step has no set timetable.
The PCAC met on 23-24 July 2026 and recommended six of the seven peptides for the FDA’s 503A bulk drug substances list. Emideltide (DSIP) was the one it rejected.
These are recommendations to the FDA, not rules: no proposed rule had appeared in the Federal Register by 3 November 2026, and the FDA still has to act: Mintz names two routes, a rule adding them to the 503A list, or a Category 1 placement, under which the FDA says it does not intend to act against pharmacies compounding the substance while it decides. The FDA’s own 503A page still shows a list amendment it proposed in 2019 waiting for a final rule. On 28 October 2026 HHS said, in an interim policy, it does not intend to act against pharmacies compounding the six under ten conditions. Full detail is in the July 2026 peptide FDA decision.

GLP-1 drugs such as semaglutide are peptides themselves, built on a gut hormone. The other peptides for GLP-1 users sit in three groups: a few you can get today, seven that an FDA committee reviewed in July 2026, six of which an HHS policy now covers on conditions, and pipeline drugs that are in trials or, for CagriSema, under FDA review.
For keeping muscle on a GLP-1, a 2025 joint advisory from four obesity and nutrition societies recommends resistance training and appropriate diet to preserve muscle.
Regulatory status varies by country, and the rules described here are the US ones. Australian residents should consult TGA guidance. UK residents should consult MHRA guidance.
Table of Contents
Disclosure: This article contains affiliate links. If you purchase through these links I may earn a small commission at no extra cost to you.
Which Peptides for GLP-1 Users Can You Get Now?
Two can be had in the United States today without waiting on regulators: tesamorelin through prescription and topical GHK-Cu, sold as a cosmetic. Sermorelin is sold too, compounded, on narrower legal footing.
Tesamorelin is FDA-approved for one use: reducing excess abdominal fat in adults with HIV-associated lipodystrophy. The EGRIFTA WR prescribing information also says it is not indicated for weight loss management, because its effect on weight is neutral. A doctor can still prescribe it off-label, meaning for a use the label doesn’t cover.
If tesamorelin is the one you want to ask about, the comparison of tesamorelin telehealth providers sets out what telehealth providers sell under its name and what a provider should require before prescribing.
The article on tesamorelin for visceral fat covers what its trials measured, how it differs from growth hormone itself, and how telehealth access works.
Sermorelin has no current FDA approval. It was once sold under one as GEREF, and in 2013 the FDA published a Federal Register determination that GEREF was not withdrawn from sale for reasons of safety or effectiveness. US telehealth providers now sell it compounded, and whether a given product is lawfully compounded is a question about that pharmacy. The prices are set out in what sermorelin costs at US telehealth providers.
GHK-Cu is sold in the United States as a topical cosmetic. Under the FDA’s rules on whether a product is a cosmetic or a drug, cosmetics need no FDA approval before sale, and which one a product is depends on its intended use. A serum sold to improve how skin looks is a cosmetic. The article on GHK-Cu for “Ozempic face” covers what it has been tested for, and the guide to GHK-Cu topical serums sets out what to look for when buying one.
Everything else here is either waiting on the FDA or still in trials.
What Happened at the July 2026 FDA Advisory Committee Meeting?
The Pharmacy Compounding Advisory Committee met on July 23 and 24, 2026, to decide what to recommend on seven peptides proposed for the Section 503A Bulk Drug Substances List. The FDA Federal Register notice published in April 2026 lists the agenda and the peptides.
Day 1 (July 23) covered BPC-157, KPV, TB-500 and MOTS-c, and Pharmaceutical Executive reported that the panel voted narrowly to recommend all four. Day 2 (July 24) covered emideltide (also called DSIP), Semax and Epitalon. Across both days the votes were close, Mintz reports: six were recommended and emideltide was voted down, and the FDA’s own scientific reviewers had recommended against all seven. The official record of the votes is the meeting video: the FDA’s meeting page carried no minutes when I checked on 3 November 2026.
Each peptide was weighed against the four criteria in 21 CFR 216.23: its physical and chemical characterisation, safety issues raised by compounding with it, the evidence of effectiveness, and its historical use in compounding.
The committee’s recommendations are advisory and not binding on the FDA, which can accept or reject them. If it agrees, Mintz names two routes: a notice-and-comment rule adding a peptide to the 503A list, or a Category 1 placement under the agency’s enforcement policy. Neither runs to a set timetable. The FDA’s 503A page still shows a list amendment proposed in 2019 waiting for a final rule, and no proposed rule on these peptides had appeared in the Federal Register by 3 November 2026.
The July meeting legalised nothing. The committee backed six of the seven, and none is on the 503A list until the FDA acts. The six are covered for now by the HHS interim policy of 28 October 2026; emideltide is not.
The article on the July 2026 peptide FDA decision explains the regulatory timeline in detail and corrects the most common misframings.
What Do the Research-Stage Peptides Under Review Address?
GLP-1 users discuss the seven for their own side effects and goals, but none was reviewed as an add-on to a GLP-1 drug. The April 2026 Federal Register notice lists the uses the FDA evaluated, and they are narrower: BPC-157 for ulcerative colitis, KPV for wound healing and inflammatory conditions, TB-500 for wound healing, MOTS-c for obesity and osteoporosis, emideltide for opioid withdrawal, chronic insomnia and narcolepsy, Semax for cerebral ischemia, migraine and trigeminal neuralgia, and Epitalon for insomnia.
Discussed for gut side effects: BPC-157 and KPV are the two discussed for gut side effects such as nausea and constipation. The article on BPC-157 and GLP-1 covers why the FDA’s own reviewers argued against listing it. KPV peptide for GLP-1 gut side effects covers KPV’s own evidence.
Recovery and tissue repair: TB-500 (a seven-amino-acid fragment of thymosin beta-4) appears in discussions about recovery capacity, wound healing, and tissue repair during the weight loss phase. The article on TB-500 and GLP-1 recovery explains why its research base is the full protein and why the FDA found no record of the fragment being given to patients.
Discussed for plateaus: MOTS-c acts on mitochondrial function in cell and mouse studies. It draws interest from GLP-1 users facing a slowdown or plateau, but whether it affects metabolic adaptation in a person is untested. The article on MOTS-c and GLP-1 covers where the exercise-mimetic label comes from and why it rests on cell and mouse work.
Discussed for sleep: Emideltide (DSIP) and Epitalon are both discussed for sleep. The article on Epitalon and sleep on GLP-1 covers the one randomised trial the FDA found, which measured melatonin and did not assess sleep. DSIP was the only one of the seven the committee voted against, Mintz reports.
Sold for cognition: Semax is a synthetic peptide marketed for focus and memory, though the FDA evaluated it for cerebral ischemia, migraine and trigeminal neuralgia. It has no US approval for any use: Drugs@FDA, the agency’s approvals database, returned nothing for it in October 2026.
None of the seven is FDA-approved, and Mintz notes that adding them to the 503A list would not be the same as an approval. The committee answered a narrower question: whether pharmacies may compound them under section 503A, which lets a pharmacy make a drug for one patient’s prescription without a new drug application.
What’s Coming in the Clinical Development Pipeline?
Three categories of medications are further along the development pathway than the research-stage peptides under PCAC review: next-generation GLP-1 combination drugs, triple-agonist medications, and myostatin inhibitors.
CagriSema combines semaglutide with cagrilintide, an amylin analogue. In the phase 3 REDEFINE 1 trial in the New England Journal of Medicine, funded by Novo Nordisk, adults without diabetes lost 20.4% of their body weight over 68 weeks on the combination, against 3.0% on placebo. The article comparing CagriSema vs semaglutide sets that against semaglutide alone. Novo Nordisk filed it with the FDA in December 2025, and it isn’t approved yet.
Retatrutide acts on three hormone receptors: GLP-1, GIP and glucagon. In the phase 3 TRIUMPH-1 trial, funded by Eli Lilly, adults with obesity and without diabetes lost 23.7% and 25.0% of their body weight on the two higher doses over 80 weeks, against 3.9% on placebo. It isn’t approved yet. The article on retatrutide and GLP-1 covers the other trials and the filing timeline.
Myostatin inhibitors block a protein that limits muscle growth, and they are being tested alongside GLP-1 drugs to cut the lean mass lost with the fat. That loss is real: in the STEP 1 trial of semaglutide, 38% of the weight lost was lean mass, according to the 2025 joint advisory. The article on myostatin inhibitors and GLP-1 muscle loss covers the trial results so far.
Each still needs FDA approval before it can be sold. None can be lawfully compounded in the meantime.
What Has Evidence for Keeping Muscle on a GLP-1?
A 2025 joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association and The Obesity Society sets out nutrition priorities for people on GLP-1 therapy. On muscle, the advisory recommends preserving muscle and bone through resistance training and appropriate diet. Research peptides don’t appear in it.
Its priorities include enough protein (the protein on GLP-1 medication article covers targets), resistance training (the GLP-1 workout guide has starting routines), managing gut side effects, and preventing nutrient deficiencies through food choices and supplements where needed.
Creatine monohydrate has a meta-analysis behind it for muscle, meaning a study that pools the results of many trials. Across 22 trials in older adults, those who took creatine during resistance training gained more lean tissue than those on placebo, according to a 2017 meta-analysis in the Open Access Journal of Sports Medicine. None of those trials involved GLP-1 medication. It needs no prescription.
The article on muscle loss on GLP-1 medication covers how much of the weight lost is lean mass and which steps have the best evidence for limiting it. On protein, the joint advisory cites 1.2 to 1.6 g per kilogram of body weight a day as a target proposed during active weight loss, and warns against prolonged intake at or above 2 g/kg.
Loose skin after fast weight loss is a common reason people look at peptides. The article on GLP-1 and loose skin covers what the rate of loss can change and what genetics, age and total weight lost decide. Topical GHK-Cu and oral collagen peptides are both sold without a prescription.
Will a Doctor Prescribe Peptides Alongside a GLP-1?
For the few with a lawful route, yes. A doctor can prescribe tesamorelin off-label, and US telehealth providers prescribe compounded sermorelin. The tesamorelin telehealth comparison shows what a provider should check before prescribing it, and what sermorelin costs at US telehealth providers lays out the monthly prices side by side.
For the seven the committee reviewed, it is narrower. Since 28 October 2026 a prescriber can write for one of the six that the HHS interim policy covers, made up by a 503A pharmacy on its conditions; emideltide is not covered. None was reviewed by the FDA as an add-on to a GLP-1 drug either.
What Should You Track Before Starting Any Peptide Protocol?
A baseline blood test gives you your own numbers to compare against later. The GLP-1 blood test comparison sets out which panel covers what, and what each costs.
Everlywell sells lab tests you order yourself, so a baseline does not have to wait for an appointment.
People researching peptides for metabolic plateau should first rule out the more common causes: inadequate protein intake (the free protein calculator provides personalised targets), insufficient training stimulus, poor sleep quality, or still being on one of the lower steps of the dose schedule, which the labels say are there to lower the risk of stomach side effects. The guide to the GLP-1 weight loss plateau sets out what to check, in order, before deciding a stall needs another drug.
The side effects tracker gives you one place to log symptoms, dose changes and anything you try. If any of these peptides do become available through compounding pharmacies after the FDA acts on the July 2026 vote, that log is how you tell whether the new thing helped or the symptom was easing on its own anyway.
What Comes After Stopping GLP-1 Medication?
People discontinuing GLP-1 medication often research peptide protocols as maintenance strategies. The article on peptide therapy after stopping GLP-1 explains why protein, resistance training and tracking stay the foundation once the medication stops.
The joint advisory counts low long-term adherence, and the weight regain that follows it, among the main problems with GLP-1 treatment. It lists nutrition for keeping weight off after stopping as an area that still needs study.
The research-stage peptides under PCAC review are not weight loss medications, and none was reviewed as an add-on to one. MOTS-c was evaluated for obesity. Its evidence rests on cell and mouse work. Treating any of them as a substitute for the medication itself mistakes what they have been tested for.
What Peptides for GLP-1 Users Are Available Right Now
Tesamorelin and cosmetic GHK-Cu are the ones you can get without waiting on the FDA, and telehealth providers also sell compounded sermorelin. The six the committee backed in July 2026 still need the FDA to act, by a rule or a Category 1 decision, before they are listed; until then pharmacies can compound them only under the HHS interim policy, and DSIP didn’t get that far. CagriSema is under FDA review, retatrutide has not been filed yet, and the myostatin inhibitors are still in trials alongside GLP-1 drugs.
For muscle, protein and resistance training are what the joint advisory recommends. The research-stage peptides have nothing comparable behind them: the FDA’s own reviewers recommended against listing all seven. Skipping the fundamentals to research peptides is optimising in the wrong order.
When a trial reads out, a compounder pulls one of these compounds, or the FDA changes its position, you’ll hear it from me along with what it means for you. The change and its context arrive in one email.
Unsubscribe anytime.
References
- US Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. fda.gov
- US Food and Drug Administration. Pharmacy Compounding Advisory Committee; Notice of Meeting. Federal Register, 16 April 2026. federalregister.gov
- 21 CFR 216.23. Bulk drug substances that can be used to compound drug products in accordance with section 503A. ecfr.gov
- FDA Panel Votes to Loosen Restrictions for Four Peptides. Pharmaceutical Executive, July 2026. pharmexec.com
- FDA’s Advisory Committee Votes on Peptides: What It Does and Doesn’t Do. Mintz, 29 July 2026. mintz.com
- EGRIFTA WR (tesamorelin) for injection. Prescribing information. DailyMed. dailymed.nlm.nih.gov
- US Food and Drug Administration. Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register, 4 March 2013. federalregister.gov
- US Food and Drug Administration. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) fda.gov
- Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1). New England Journal of Medicine, 2025;393:635-647. Funded by Novo Nordisk. doi.org
- Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1). New England Journal of Medicine, 2026. Funded by Eli Lilly. nejm.org
- Mozaffarian D, et al. Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society. American Journal of Lifestyle Medicine, 2025. pmc.ncbi.nlm.nih.gov
- Chilibeck PD, et al. Effect of creatine supplementation during resistance training on lean tissue mass and muscular strength in older adults: a meta-analysis. Open Access Journal of Sports Medicine, 2017;8:213-226. pmc.ncbi.nlm.nih.gov
- Novo Nordisk. Novo Nordisk files for FDA approval of CagriSema. News release, 18 December 2025. novonordisk.com
- US Food and Drug Administration. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee. fda.gov
- US Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. accessdata.fda.gov
